Literature DB >> 15096354

Ezetimibe and statin-associated myopathy.

Richard Fux, Klaus Mörike, Udo-Frank Gundel, Rüdiger Hartmann, Christoph H Gleiter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15096354     DOI： 10.7326/0003-4819-140-8-200404200-00034

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  15 in total

Review 1.  Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.

Authors:  Benjamin J Ansell
Journal:  Curr Atheroscler Rep       Date:  2005-02       Impact factor: 5.113

2.  Asymptomatic hypothyroidism and statin-induced myopathy.

Authors:  Simona L Bar; Daniel T Holmes; Jiri Frohlich
Journal:  Can Fam Physician       Date:  2007-03       Impact factor: 3.275

3.  Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial.

Authors:  Heiner K Berthold; Ali Naini; Salvatore Di Mauro; Maarit Hallikainen; Helena Gylling; Wilhelm Krone; Ioanna Gouni-Berthold
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Mechanisms and assessment of statin-related muscular adverse effects.

Authors:  Dirk Moßhammer; Elke Schaeffeler; Matthias Schwab; Klaus Mörike
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

Review 5.  Update on toxic myopathies.

Authors:  F L Mastaglia; M Needham
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

Review 6.  [Myopathies under therapy with lipid-lowering agents].

Authors:  H Köller; O Neuhaus; M Schroeter; H-P Hartung
Journal:  Nervenarzt       Date:  2005-02       Impact factor: 1.214

Review 7.  Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Authors:  Yiannis S Chatzizisis; Konstantinos C Koskinas; Gesthimani Misirli; Christos Vaklavas; Apostolos Hatzitolios; George D Giannoglou
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

Review 8.  Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways.

Authors:  Shailendra B Patel
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

9.  Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Authors:  Chantale Simard; Paul Poirier
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

Review 10.  Impact of ezetimibe on atherosclerosis: is the jury still out?

Authors:  Firas J Al Badarin; Iftikhar J Kullo; Stephen L Kopecky; Randal J Thomas
Journal:  Mayo Clin Proc       Date:  2009-04       Impact factor: 7.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.